VERA

Vera Therapeutics, Inc. [VERA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VERA Stock Summary

Top 10 Correlated Stocks

VERA

In the News

VERA Financial details

Company Rating
-
Market Cap
2.63B
Income
-95.68M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.33
Forward P/E
-
PEG
2.61
P/S
-
P/B
6.9
P/C
-
P/FCF
-9.69
Quick Ratio
6.5
Current Ratio
6.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.28
EPS next Y
-
EPS next Q
-
EPS this Y
-32.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
28.89%
-
-
-
-
SMA20
16.42%
SMA50
1.28%
SMA100
-27.73%
Inst Own
-
Inst Trans
-
ROA
-58%
ROE
-82%
ROC
-0.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.05-50.78
52W High
-54.52%
52W Low
+279%
RSI
48.3
Rel Volume
0.92
Avg Volume
1.38M
Volume
1.27M
Perf Week
-28.94%
Perf Month
-4.25%
Perf Quarter
-45.02%
Perf Half Y
-51.05%
-
-
-
-
Beta
1.049
-
-
Volatility
2.86%, 3.66%
Prev Close
0.98%
Price
22.74
Change
3.08%

Something similar

Top by Market Cap
M&M.NS
APC.DE
MSF.DE
VOO
MSFT
Same Sector
FONR
ZNTL
0J5Q.L
VRPX
0GZV.IL
Top Correlated Stocks
002010.SZ
URU.L
2168.T
LYRA
PET.L
Similar Market Cap
ROIC
BB
600193.SS
000626.SZ
1769.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 1.38M
  • Market Capitalization 2.63B
  • Employee 51
  • CEO Dr. Marshall W. Fordyce M.D.
  • Headquarters Brisbane,CA,US
  • IPO Date 2021-05-14
  • Website https://veratx.com

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.